The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells

British Journal of Pharmacology

Volumn 162, Issue 7, 2011, Pages 1590-1602

  Tiffon, C E ^a   Adams, J E ^a   Van Der Fits, L ^b   Wen, S ^c   Townsend, P A ^a   Ganesan, A ^c   Hodges, E ^d   Vermeer, M H ^b   Packham, G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

cutaneous T cell lymphoma; cytokine; histone deacetylase; interleukin 10; romidepsin; STAT3; vorinostat

Indexed keywords

GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LIPOCORTIN 5; PROPIDIUM IODIDE; ROMIDEPSIN; STAT3 PROTEIN; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE PARAMETERS; CELL CYCLE PROGRESSION; CELL DEATH; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DEPSIPEPTIDES; DOWN-REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; LYMPHOMA, T-CELL, CUTANEOUS; RECEPTORS, INTERFERON; STAT3 TRANSCRIPTION FACTOR;

EID: 79952394059     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01188.x     Document Type: Article

References (57)

1. Ansel KM, Djuretic I, Tanasa B, Rao A, (2006). Regulation of Th2 differentiation and IL-4 locus accessibility. Annu Rev Immunol 24: 607-656.
2. Asadullah K, Docke WD, Haeussler A, Sterry W, Volk HD, (1996). Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 107: 833-837. (Pubitemid 26408200)
3. Berger CL, Hanlon D, Kanada D, Dhodapkar M, Lombillo V, Wang N, et al. (2002). The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 99: 2929-2939. (Pubitemid 34525383)
4. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, et al. (2005). Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 105: 1640-1647. (Pubitemid 40223685)
5. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM, (2003). Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279. (Pubitemid 36348705)
6. Bolden JE, Peart MJ, Johnstone RW, (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784. (Pubitemid 44348499)
7. Buglio D, Georgiakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, et al. (2008). Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112: 1424-1433.
8. Buhl L, Sogaard H, (1997). Immunohistochemical expression of IL-10 in mycosis fungoides. Exp Dermatol 6: 195-198. (Pubitemid 27372092)
9. Bunn PA, Jr, Foss FM, (1996). T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem Suppl 24: 12-23.
10. Campbell JJ, Clark RA, Watanabe R, Kupper TS, (2010). Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116: 767-771.
11. Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R, et al. (2009). Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood 113: 4038-4048.
12. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840.
13. Crabb SJ, Howell M, Rogers H, Ishfaq M, Yurek-George A, Carey K, et al. (2008). Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. Biochem Pharmacol 76: 463-475.
14. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39. (Pubitemid 46053039)
15. Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, et al. (2008). Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 68: 3785-3794.
16. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. (2002). FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916-4921. (Pubitemid 34984414)
17. Harada T, Kyttaris V, Li Y, Juang YT, Wang Y, Tsokos GC, (2007). Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity 40: 1-8. (Pubitemid 46332416)
18. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, et al. (2007). A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67: 9630-9636. (Pubitemid 47621208)
19. Kaltoft K, Bisballe S, Rasmussen HF, Thestrup-Pedersen K, Thomsen K, Sterry W, (1987). A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 279: 293-298. (Pubitemid 17092161)
20. Kasprzycka M, Zhang Q, Witkiewicz A, Marzec M, Potoczek M, Liu X, et al. (2008). Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol 181: 2506-2512.
21. van Kester MS, Out-Luiting JJ, von dem Borne PA, Willemze R, Tensen CP, Vermeer MH, (2008). Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells. J Invest Dermatol 128: 1691-1695. (Pubitemid 351847375)
22. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. (2008). Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589. (Pubitemid 351184977)
23. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. (2005). Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115: 798-812. (Pubitemid 40489380)
24. Kim EJ, Lin J, Junkins-Hopkins JM, Vittorio CC, Rook AH, (2006). Mycosis fungoides and sezary syndrome: an update. Curr Oncol Rep 8: 376-386. (Pubitemid 44336299)
25. Krejsgaard T, Gjerdrum LM, Ralfkiaer E, Lauenborg B, Eriksen KW, Mathiesen AM, et al. (2008). Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 22: 2230-2239.
26. Luftl M, Feng A, Licha E, Schuler G, (2002). Dendritic cells and apoptosis in mycosis fungoides. Br J Dermatol 147: 1171-1179. (Pubitemid 36963024)
27. Marks PA, Richon VM, Miller T, Kelly WK, (2004). Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168. (Pubitemid 39140958)
28. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, et al. (2003). Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115: 751-763. (Pubitemid 38030303)
29. Mishra N, Brown DR, Olorenshaw IM, Kammer GM, (2001). Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci USA 98: 2628-2633. (Pubitemid 32209533)
30. Mitchell TJ, John S, (2005). Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology 114: 301-312. (Pubitemid 40314803)
31. Mosser DM, Zhang X, (2008). Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226: 205-218.
32. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. (2007). Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25: 3109-3115. (Pubitemid 47218059)
33. Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, et al. (2007). Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26: 1166-1177.
34. Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, et al. (2004). T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103: 4636-4643. (Pubitemid 38745996)
35. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. (2009). Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27: 5410-5417.
36. Ray S, Sherman CT, Lu M, Brasier AR, (2002). Angiotensinogen gene expression is dependent on signal transducer and activator of transcription 3-mediated p300/cAMP response element binding protein-binding protein coactivator recruitment and histone acetyltransferase activity. Mol Endocrinol 16: 824-836. (Pubitemid 34297750)
37. Ray S, Lee C, Hou T, Boldogh I, Brasier AR, (2008). Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res 36: 4510-4520.
38. Richon VM, Garcia-Vargas J, Hardwick JS, (2009). Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280: 201-210.
39. Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U, et al. (1997). Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 185: 825-831. (Pubitemid 27119866)
40. Saraiva M, O'Garra A, (2010). The regulation of IL-10 production by immune cells. Nat Rev Immunol 10: 170-181.
41. Scarisbrick JJ, (2006). Staging and management of cutaneous T-cell lymphoma. Clin Exp Dermatol 31: 181-186.
42. Schust J, Sperl B, Hollis A, Mayer TU, Berg T, (2006). Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13: 1235-1242. (Pubitemid 44750735)
43. Shohat M, Hodak E, Sredni B, Shohat B, Sredni D, David M, (2001). Cytokine profile of patients with mycosis fungoides and the immunomodulatory effect of AS101. Acta Derm Venereol 81: 255-257. (Pubitemid 32977103)
44. Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB, (2009). HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 20: 1293-1302.
45. Szabo SJ, Dighe AS, Gubler U, Murphy KM, (1997). Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 185: 817-824. (Pubitemid 27119865)
46. Togi S, Kamitani S, Kawakami S, Ikeda O, Muromoto R, Nanbo A, et al. (2009). HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A. Biochem Biophys Res Commun 379: 616-620.
47. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, et al. (2009). The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10: 92-100.
48. Wen S, Packham G, Ganesan A, (2008). Macrolactamization versus macrolactonization: total synthesis of FK228, the depsipeptide histone deacetylase inhibitor. J Org Chem 73: 9353-9361.
49. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. (2005). WHO-EORTC classification for cutaneous lymphomas. Blood 105: 3768-3785. (Pubitemid 40656118)
50. Wozniak MB, Villuendas R, Bischoff JR, Blanco-Aparicio C, Martinez Leal JF, de La Cueva P, et al. (2010). Vorinostat interferes with the signaling transduction pathway of T cell receptor and synergizes with PI3K inhibitors in cutaneous T-cell lymphoma. Haematologica 95: 613-621.
51. Wu C, Warrier RR, Wang X, Presky DH, Gately MK, (1997). Regulation of interleukin-12 receptor beta1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells. Eur J Immunol 27: 147-154. (Pubitemid 27046071)
52. Yoo EK, Cassin M, Lessin SR, Rook AH, (2001). Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol 45: 208-216. (Pubitemid 32729303)
53. Yu H, Pardoll D, Jove R, (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
54. Yuan ZL, Guan YJ, Chatterjee D, Chin YE, (2005). Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307: 269-273. (Pubitemid 40116244)
55. Yurek-George A, Cecil AR, Mo AH, Wen S, Rogers H, Habens F, et al. (2007). The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor. J Med Chem 50: 5720-5726. (Pubitemid 350106026)
56. Zaki MH, Shane RB, Geng Y, Showe LC, Everetts SE, Presky DH, et al. (2001). Dysregulation of lymphocyte interleukin-12 receptor expression in Sezary syndrome. J Invest Dermatol 117: 119-127. (Pubitemid 32652448)
57. Zhang C, Richon V, Ni X, Talpur R, Duvic M, (2005). Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125: 1045-1052.